Combination antimicrobial therapy for bacterial infections - Guidelines for the clinician

被引:96
作者
Rybak, MJ
McGrath, BJ
机构
[1] DETROIT RECEIVING HOSP & UNIV HLTH CTR,DEPT PHARM,DETROIT,MI
[2] ANTIINFECT RES LAB,DETROIT,MI
[3] GRACE HOSP,DEPT PHARM,DETROIT,MI
[4] WAYNE STATE UNIV,DETROIT,MI
关键词
D O I
10.2165/00003495-199652030-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Therapy with antimicrobial combinations has been used as long as antimicrobials have been available. Combinations of antibiotics are often used to take advantage of different mechanisms of action and/or toxicity profiles. Well established indications for combination antimicrobial therapy include: (a) empirical treatment of life-threatening infections; (b) treatment of polymicrobial infections; (c) prevention of the emergence of bacterial resistance; and (d) for synergism. Disadvantages of combination therapy include: (a) increased expense; (b) increased risk of adverse effects; (c) antagonism; and (d) superinfection. Combination antimicrobial therapy should be considered for the treatment of serious Gram-negative infections caused by Enterobacter cloacae, Pseudomonas aeruginosa and Serratia marcescens, and certain Gram-positive infections caused by Enterococcus spp. and Staphylococcus spp. Selection of agents should be dependent upon local susceptibility patterns, clinical experience, site of infection, potential toxicities and cost.
引用
收藏
页码:390 / 405
页数:16
相关论文
共 109 条
[61]   COMPARATIVE INVITRO AND INVIVO ACTIVITIES OF PIPERACILLIN COMBINED WITH THE BETA-LACTAMASE INHIBITORS TAZOBACTAM, CLAVULANIC ACID, AND SULBACTAM [J].
KUCK, NA ;
JACOBUS, NV ;
PETERSEN, PJ ;
WEISS, WJ ;
TESTA, RT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (11) :1964-1969
[62]   NOVEL ANTIBIOTIC REGIMENS AGAINST ENTEROCOCCUS-FAECIUM RESISTANT TO AMPICILLIN, VANCOMYCIN, AND GENTAMICIN [J].
LANDMAN, D ;
MOBARAKAI, NK ;
QUALE, JM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (09) :1904-1908
[63]   EFFECTS OF COMBINATIONS OF BETA-LACTAMS, DAPTOMYCIN, GENTAMICIN, AND GLYCOPEPTIDES AGAINST GLYCOPEPTIDE-RESISTANT ENTEROCOCCI [J].
LECLERCQ, R ;
BINGEN, E ;
SU, QH ;
LAMBERTZECHOVSKI, N ;
COURVALIN, P ;
DUVAL, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (01) :92-98
[64]  
LEGGETT JE, 1991, SCAND J INFECT DIS S, V74, P179
[65]  
LEIGH D, 1986, Journal of Antimicrobial Chemotherapy, V17, P1
[66]   SLOW RESPONSE TO VANCOMYCIN OR VANCOMYCIN PLUS RIFAMPIN IN METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS ENDOCARDITIS [J].
LEVINE, DP ;
FROMM, BS ;
REDDY, BR .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (09) :674-680
[67]  
Lorian V., 1991, ANTIBIOTICS LAB MED, V3rd, P434
[68]   SYNERGY OF PENICILLIN AND DECREASING CONCENTRATIONS OF AMINOGLYCOSIDES AGAINST ENTEROCOCCI FROM PATIENTS WITH INFECTIVE ENDOCARDITIS [J].
MATSUMOTO, JY ;
WILSON, WR ;
WRIGHT, AJ ;
GERACI, JE ;
WASHINGTON, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 18 (06) :944-947
[69]   EVALUATION OF NEW ANTIINFECTIVE DRUGS FOR THE TREATMENT OF ACUTE BACTERIAL-MENINGITIS [J].
MCCRACKEN, GH ;
SANDE, MA ;
LENTNEK, A ;
WHITLEY, RJ ;
SCHELD, WM .
CLINICAL INFECTIOUS DISEASES, 1992, 15 :S182-S188
[70]  
MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033